Lucid Diagnostics Inc. $LUCD Shares Purchased by Aberdeen Group plc

Aberdeen Group plc boosted its stake in Lucid Diagnostics Inc. (NASDAQ:LUCD) by 38.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,457,894 shares of the company’s stock after acquiring an additional 957,894 shares during the period. Aberdeen Group plc owned 2.51% of Lucid Diagnostics worth $3,769,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Perkins Capital Management Inc. acquired a new stake in shares of Lucid Diagnostics during the third quarter worth $1,138,000. Ghisallo Capital Management LLC acquired a new stake in shares of Lucid Diagnostics during the third quarter worth $2,990,000. Masters Capital Management LLC raised its holdings in shares of Lucid Diagnostics by 46.6% during the third quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after purchasing an additional 1,272,000 shares during the period. Vanguard Group Inc. raised its holdings in shares of Lucid Diagnostics by 9.6% during the third quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock worth $4,569,000 after purchasing an additional 396,719 shares during the period. Finally, Two Seas Capital LP acquired a new stake in shares of Lucid Diagnostics during the third quarter worth $3,030,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Stock Performance

Lucid Diagnostics stock opened at $1.12 on Thursday. The company has a 50-day simple moving average of $1.29 and a 200-day simple moving average of $1.18. The firm has a market capitalization of $198.18 million, a P/E ratio of -1.17 and a beta of 1.24. Lucid Diagnostics Inc. has a one year low of $0.95 and a one year high of $1.70.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The firm had revenue of $1.50 million for the quarter, compared to analyst estimates of $1.39 million. As a group, sell-side analysts forecast that Lucid Diagnostics Inc. will post -0.84 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Ascendiant Capital Markets increased their target price on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a report on Thursday, March 26th. Wall Street Zen raised shares of Lucid Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, BTIG Research reissued a “buy” rating and set a $2.50 target price on shares of Lucid Diagnostics in a report on Monday, March 30th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $3.94.

Lucid Diagnostics Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.